Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 3393 clinical trials
Featured trial
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT)

participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the

primary cancer
  • 07 Mar, 2023
  • 4 locations
Featured trial
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)  

Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former …

  • 21 Mar, 2023
  • 82 locations
Featured trial
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (202200050434)

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation

  • 20 Dec, 2022
  • 24 locations
Featured trial
  • 19 Dec, 2022
  • 120 locations
Featured trial
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)

evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving lung function at Week 24 compared to

  • 06 Mar, 2023
  • 71 locations
Featured trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

  • 28 Oct, 2022
  • 13 locations
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

measurable disease
bladder tumor
cancer of the ovary
  • 11 Jul, 2022
  • 19 locations
Featured trial
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)  

progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous non-small-cell lung cancer (NSCLC) expressing CEACAM5 greater than or equal to 2+ in intensity in at

  • 17 Feb, 2023
  • 5 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210) (FIGHT-210)

This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options

lung carcinoma
measurable disease
  • 28 Oct, 2022
  • 17 locations
Featured trial
Lung Nodules – Scheduled or Planned Biopsy

It's estimated that 1.5 million new cases of lung nodules are found per year in the United States. The goal in managing this condition is to rapidly identify and resect malignant nodules and avoid

  • 23 Nov, 2020
  • 1 location